Figure 5From: BAP31, a promising target for the immunotherapy of malignant melanomasLDH release assay for cytotoxicity of CTLs from mBAP31 vaccinated mice against murine cancer cell lines. Cytotoxic activities of CTLs isolated from the splenocytes of the p-LAMP/mBAP31 vaccinated C57BL/6 mice (H-2b) against mBAP31 peptides pulsed mouse colon cancer cell lines CT26 (H-2d), 2E8 (mBAP31 depleted B16 cells, H-2b) and B16 (H-2b) were detected by LDH release assay at effector-to-target ratio of 50:1. Peptides used were indicated in abscissa (A-C). Cytotoxic activities of CTLs from p-LAMP/mBAP31 (△), p-mBAP31 (□) or PBS (○) vaccinated C57BL/6 mice (H-2b) against B16 cells pulsed with mBAP31149–157 expressing both H-2b and mBAP31 (D), 2E8 cells (mBAP31 depleted B16 cells) pulsed with mBAP31149–157 expressing H-2b but much lower mBAP31 than B16 cells (E), CT26 cells pulsed with mBAP31149–157 expressing H-2d and mBAP31 (F), B16 cells expressing both H-2b and mBAP31 (G), 2E8 cells expressing H-2b but much lower mBAP31 than B16 cells (H) and CT26 cells expressing H-2d and mBAP31 (I).Back to article page